Gastrointestinal Cancer News

Microbiota profiles associated with colorectal cancer were found to be different from those in individuals without colorectal cancer in a recent study. Moreover, bacterial clusters associated with colorectal cancer were found to be differentially correlated with mucosal gene-expression profiles.

Patients with chronic hepatitis B virus infection treated with nucleos(t)ide analogues showed a reduced risk for hepatocellular carcinoma recurrence compared with patients untreated with nucleos(t)ide analogues, according to published findings.

Clifford A. Hudis, MD, FACP, has been named the next CEO of ASCO.

Statin use was associated with a reduced risk for colorectal cancer in patients with inflammatory bowel diseases, according to a recent study published in Clinical Gastroenterology and Hepatology.

This HemOnc Today supplement provides coverage of the major findings presented at the meeting, including results from the CheckMate-032 and NEOSCOPE trials. Perspectives from experts in the fields of oncology, gastroenterology and surgery provide further insight into the potential implications of these results in everyday practice.

Aspirin, and, to a lesser extent, vitamin D, have both been shown to aid in the prevention of colon cancer, and vitamin D may also have a role in the treatment of the disease, according to Tanios Bekaii-Saab, MD, a professor of medicine and pharmacy at The Ohio State University College of Medicine.

Despite considerable advancements made in cancer treatment — such as with precision medicine, genomic profiling and immunotherapies — persistent financial, coverage and delivery issues threaten patients’ access to these modalities, according to ASCO’s “State of Cancer Care in America: 2016” report.

Prior research has shown patients with cancer who are more functional and active tend to achieve better outcomes on chemotherapy.

One year of low-dose metformin reduced the prevalence and number of metachronous adenomas after polypectomy in nondiabetic adults, according to the results of a phase 3 randomized controlled trial.

ASCO today announced it has started recruiting patients for its Targeted Agent and Profiling Utilization Registry study, commonly referred to as the TAPUR trial.